Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2194
Peer-review started: January 25, 2024
First decision: February 8, 2024
Revised: February 9, 2024
Accepted: March 27, 2024
Article in press: March 27, 2024
Published online: May 6, 2024
Gastroesophageal reflux disease (GERD) is a common complication of esophageal cancer surgery that can affect quality of life and increase the risk of esophageal stricture and anastomotic leakage. Wendan Decoction (WDD) is a traditional Chinese herbal formula used to treat various gastrointestinal disorders, such as gastritis, functional dyspepsia, and irritable bowel syndrome. Mosapride, a prokinetic agent, functions as a selective 5-hydroxytryptamine 4 agonist, enhan
To evaluate the therapeutic effects of WDD combined with mosapride on GERD after esophageal cancer surgery.
Eighty patients with GERD were randomly divided into treatment (receiving WDD combined with mosapride) and control (receiving mosapride alone) groups. The treatment was conducted from January 2021 to January 2023. The primary outcome was improved GERD symptoms as measured using the reflux disease questionnaire (RDQ). The secondary outcomes were improved esophageal mo
The treatment group showed a notably reduced RDQ score and improved eso
WDD combined with mosapride is an effective and safe therapy for GERD after esophageal cancer surgery. It can improve GERD symptoms, esophageal motility, gastric emptying, and the quality of life of patients. Further studies with larger sample sizes and longer follow-up periods are required to confirm these findings.
Core Tip: This study suggests that combining Wendan Decoction with mosapride is an effective and safe therapy for mana